BeiGene OK'd to Test PARP Inhibitor in China

BeiGene, a Beijing oncology biopharma, received approval from the CFDA to begin China trials of BGB-290, a PARP1/2 inhibitor. Trials of BGB-290 are already underway in Australia and the US. BeiGene believes BGB-290 will prove to be a more selective inhibitor of PARP 1/2 than its competitors, decreasing the side effects and increasing efficacy, in patients with solid tumors. BeiGene also pointed out that BGB-290 is the third of the company's programs to be approved for China trials. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //